AAAAAA

   
Results: 1-25 | 26-26
Results: 1-25/26
Long-term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation
Authors: Shimoni, A Gajewski, J Donato, M Martin, T O'Brien, S Talpaz, M Cohen, A Korbling, M Champlin, R Giralt, S
Citation: A. Shimoni et al., Long-term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation, BIOL BLOOD, 7(10), 2001, pp. 568-575
Adenovirus infections in adult recipients of blood and marrow transplants
Authors: La Rosa, AM Champlin, RE Mirza, N Gajewski, J Giralt, S Rolston, KV Raad, I Jacobson, K Kontoyiannis, D Elting, L Whimbey, E
Citation: Am. La Rosa et al., Adenovirus infections in adult recipients of blood and marrow transplants, CLIN INF D, 32(6), 2001, pp. 871-876
Impact of high-dose chemotherapy on peripheral T-cell lymphomas
Authors: Rodriguez, J Munsell, M Yazji, S Hagemeister, FB Younes, A Andersson, B Giralt, S Gajewski, J de Lima, M Couriel, D Romaguera, J Cobanillas, FF Champlin, RE Khouri, IF
Citation: J. Rodriguez et al., Impact of high-dose chemotherapy on peripheral T-cell lymphomas, J CL ONCOL, 19(17), 2001, pp. 3766-3770
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia
Authors: Bibawi, S Abi-Said, D Fayad, L Anderlini, P Ueno, NT Mehra, R Khouri, I Giralt, S Gajewski, J Donato, M Claxton, D Braunschweig, I van Besien, K Andreeff, M Andersson, BS Estey, EH Champlin, R Przepiorka, D
Citation: S. Bibawi et al., Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia, AM J HEMAT, 67(4), 2001, pp. 227-233
Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival
Authors: van Besien, K Rodriguez, A Tomany, S Younes, A Donate, M Sarris, A Giralt, S Mehra, R Andersson, B Gajewski, J Champlin, R Cabanillas, F
Citation: K. Van Besien et al., Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival, BONE MAR TR, 27(4), 2001, pp. 397-404
Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation
Authors: Champlin, R Khouri, I Anderlini, P Gajewski, J Kornblau, S Molldrem, J Shimoni, A Ueno, N Giralt, S
Citation: R. Champlin et al., Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation, BONE MAR TR, 27, 2001, pp. S13-S22
Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study
Authors: Ravandi, F Kantarjian, H Cohen, A Davis, M O'Brien, S Anderlini, P Andersson, B Claxton, D Donato, M Gajewski, J Khouri, I Korbling, M Ueno, N deVos, D Champlin, R Giralt, S
Citation: F. Ravandi et al., Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study, BONE MAR TR, 27(12), 2001, pp. 1221-1225
Terminal nucleotidyl transferase activity of recombinant Flaviviridae RNA-dependent RNA polymerases: Implication for viral RNA synthesis
Authors: Ranjith-Kumar, CT Gajewski, J Gutshall, L Maley, D Sarisky, RT Kao, CC
Citation: Ct. Ranjith-kumar et al., Terminal nucleotidyl transferase activity of recombinant Flaviviridae RNA-dependent RNA polymerases: Implication for viral RNA synthesis, J VIROLOGY, 75(18), 2001, pp. 8615-8623
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
Authors: Giralt, S Thall, PF Khouri, I Wang, XM Braunschweig, I Ippolitti, C Claxton, D Donato, M Bruton, J Cohen, A Davis, M Andersson, BS Anderlini, P Gajewski, J Kornblau, S Andreeff, M Przepiorka, D Ueno, NT Molldrem, J Champlin, R
Citation: S. Giralt et al., Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation, BLOOD, 97(3), 2001, pp. 631-637
High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer
Authors: Braunschweig, I Mirza, NQ Rondon, G Lauppe, J Mehra, R Gajewski, J Korbling, M Huh, YO Geisler, D Gee, AP Champlin, R Przepiorka, D
Citation: I. Braunschweig et al., High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer, CYTOTHERAPY, 2(2), 2000, pp. 105-110
Tacrolimus does not abrogate the increased risk of acute graft-versus-hostdisease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB I and HLA-DQB I
Authors: Przepiorka, D Saliba, R Cleary, K Fischer, H Tonai, R Fritsche, H Khouri, IF Folloder, J Ueno, NT Mehra, R Ippoliti, C Giralt, S Gajewski, J Donato, M Claxton, D Braunschweig, I van Besien, K Anderlini, P Andersson, BS Champlin, R
Citation: D. Przepiorka et al., Tacrolimus does not abrogate the increased risk of acute graft-versus-hostdisease after unrelated-donor marrow transplantation with allelic mismatching at HLA-DRB I and HLA-DQB I, BIOL BLOOD, 6(2A), 2000, pp. 190-197
High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant
Authors: de Lima, M van Besien, K Gajewski, J Khouri, I Andersson, B Korbling, M Champlin, R Giralt, S
Citation: M. De Lima et al., High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant, BONE MAR TR, 26(3), 2000, pp. 333-338
Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy)
Authors: Andersson, BS Gajewski, J Donato, M Giralt, S Gian, V Wingard, J Tarantolo, S Fernandez, H Hu, WW Blume, K Kashyap, A Forman, SJ Champlin, RE
Citation: Bs. Andersson et al., Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy), BONE MAR TR, 25, 2000, pp. S35-S38
Noncyclic operations and the LCA in a derivational theory
Authors: Gajewski, J
Citation: J. Gajewski, Noncyclic operations and the LCA in a derivational theory, LINGUIST IN, 31(4), 2000, pp. 722-731
Harnessing graft-versus-malignancy: Non-myeloablative preparative regimensfor allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy
Authors: Champlin, R Khouri, I Shimoni, A Gajewski, J Kornblau, S Molldrem, J Ueno, N Giralt, S Anderlini, P
Citation: R. Champlin et al., Harnessing graft-versus-malignancy: Non-myeloablative preparative regimensfor allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy, BR J HAEM, 111(1), 2000, pp. 18-29
Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program
Authors: Davies, SM Kollman, C Anasetti, C Antin, JH Gajewski, J Casper, JT Nademanee, A Noreen, H King, R Confer, D Kernan, NA
Citation: Sm. Davies et al., Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program, BLOOD, 96(13), 2000, pp. 4096-4102
Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease
Authors: Przepiorka, D Kernan, NA Ippoliti, C Papadopoulos, EB Giralt, S Khouri, I Lu, JG Gajewski, J Durett, A Cleary, K Champlin, R Andersson, BS Light, S
Citation: D. Przepiorka et al., Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease, BLOOD, 95(1), 2000, pp. 83-89
Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia
Authors: Sacchi, S Kantarjian, HM Freireich, EJ O'Brien, SO Cortes, J Rios, MB Kornblau, S Giles, FJ Koller, C Gajewski, J Talpaz, M
Citation: S. Sacchi et al., Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia, LEUK LYMPH, 35(5-6), 1999, pp. 483-489
Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma
Authors: Przepiorka, D van Besien, K Khouri, I Hagemeister, F Samuels, B Folloder, J Ueno, NT Molldrem, J Mehra, R Korbling, M Giralt, S Gajewski, J Donato, M Cleary, K Claxton, D Braunschweig, I Andersson, B Anderlini, P Champlin, R
Citation: D. Przepiorka et al., Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma, ANN ONCOL, 10(5), 1999, pp. 527-532
Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy
Authors: Khouri, IF Lee, MS Romaguera, J Mirza, N Kantarjian, H Korbling, M Albitar, M Giralt, S Samuels, B Anderlini, P Rodriguez, J von Wolff, B Gajewski, J Cabanillas, F Champlin, R
Citation: If. Khouri et al., Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy, ANN ONCOL, 10(11), 1999, pp. 1293-1299
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation
Authors: Przepiorka, D Khouri, I Ippoliti, C Ueno, NT Mehra, R Korbling, M Giralt, S Gajewski, J Fischer, H Donato, M Cleary, K Claxton, D Chan, KW Braunschweig, I van Besien, K Andersson, BS Anderlini, P Champlin, R
Citation: D. Przepiorka et al., Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation, BONE MAR TR, 24(7), 1999, pp. 763-768
Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia
Authors: Przepiorka, D Khouri, I Thall, P Mehra, R Lee, MS Ippoliti, C Giralt, S Gajewski, J van Besien, K Andersson, B Korbling, M Deisseroth, AB Champlin, R
Citation: D. Przepiorka et al., Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia, BONE MAR TR, 23(10), 1999, pp. 977-981
Long-term followup of the North American multicenter UroLume trial for the treatment of external detrusor-sphincter dyssynergia
Authors: Chancellor, MB Gajewski, J Ackman, CFD Appell, RA Bennett, J Binard, J Boone, TB Chetner, MP Crewalk, JA Defalco, A Foote, J Green, B Juma, S Jung, SY Linsenmeyer, TA MacMillan, R Mayo, M Ozawa, H Roehrborn, CG Shenot, PJ Stone, A Vazquez, A Killorin, W Rivas, DA
Citation: Mb. Chancellor et al., Long-term followup of the North American multicenter UroLume trial for the treatment of external detrusor-sphincter dyssynergia, J UROL, 161(5), 1999, pp. 1545-1550
Primary refractory and relapsed adult acute lymphoblastic leukemia - Characteristics, treatment results, and prognosis with salvage therapy
Authors: Thomas, DA Kantarjian, H Smith, TL Koller, C Cortes, J O'Brien, S Giles, FJ Gajewski, J Pierce, S Keating, MJ
Citation: Da. Thomas et al., Primary refractory and relapsed adult acute lymphoblastic leukemia - Characteristics, treatment results, and prognosis with salvage therapy, CANCER, 86(7), 1999, pp. 1216-1230
Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation
Authors: Przepiorka, D Smith, TL Folloder, J Khouri, I Ueno, NT Mehra, R Korbling, M Huh, YO Giralt, S Gajewski, J Donato, M Cleary, K Claxton, D Braunschweig, I van Besien, K Andersson, BS Anderlini, P Champlin, R
Citation: D. Przepiorka et al., Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation, BLOOD, 94(4), 1999, pp. 1465-1470
Risultati: 1-25 | 26-26